Organon & Company
Research Organon & Company (OGN) on Bullrun: valuation model: 7.4% overvalued, market cap USD 3.61B, P/E 17.6, dividend yield 0.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOGN
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal7.4% overvalued
- Market capUSD 3.61B
- P/E17.6
- Dividend yield0.6%
- Financial periodQ2 2026
- RevenueUSD 1.56B
- Net incomeUSD 108.00M
- Free cash flowUSD 31.00M
- Gross margin54.4%
Valuation Snapshot
Bullrun's latest valuation model marks Organon & Company as 7.4% overvalued; latest market cap is USD 3.61B; P/E is 17.6; dividend yield is 0.6%.
Peer valuation comparison
Latest P/E is 17.61x versus a Healthcare sector median of 24.46x (28.0% below).
Latest dividend yield is 0.58% versus a Healthcare sector median of 2.11% (72.5% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 6.22B | USD 187.00M | USD 538.00M | 53.3% | 0.72 | USD 574.00M | USD 8.64B | USD 752.00M |
| FY2024 | USD 6.40B | USD 864.00M | USD 764.00M | 58.0% | 3.33 | USD 675.00M | USD 8.88B | USD 472.00M |
| FY2023 | USD 6.26B | USD 1.02B | USD 548.00M | 59.8% | 3.99 | USD 693.00M | USD 8.76B | -USD 70.00M |
| FY2022 | USD 6.17B | USD 917.00M | USD 662.00M | 62.8% | 3.59 | USD 706.00M | USD 8.91B | -USD 892.00M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.61B | 17.6 | 0.6% | 0.08 |
| 2025 | 2025-12-31 | USD 1.87B | 10.0 | 4.7% | 0.34 |
| 2024 | 2024-12-31 | USD 3.85B | 4.5 | 7.5% | 1.12 |
| 2023 | 2023-12-29 | USD 3.69B | 6.3 | 7.8% | 1.12 |
| 2022 | 2022-12-30 | USD 7.10B | 7.0 | 4.0% | 1.12 |
| 2021 | 2021-12-31 | USD 7.72B | 5.7 | 1.8% | 0.56 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.08 USD, yield 0.6%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.34 USD |
| FY2024 | 1.12 USD |
| FY2023 | 1.12 USD |
| FY2022 | 1.12 USD |
About Organon & Company
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Organon & Company overvalued or undervalued?
Bullrun's valuation model currently marks Organon & Company as 7.4% overvalued.
What is Organon & Company's market cap?
Organon & Company's market capitalization is USD 3.61B.
What is Organon & Company's P/E ratio?
Organon & Company's price-to-earnings (P/E) ratio is 17.6.
Does Organon & Company pay a dividend?
Organon & Company has a dividend yield of 0.6%.
What does Organon & Company do?
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.